bioAffinity Technologies, Inc. Cost of Revenue
bioAffinity Technologies, Inc. (BIAF) reported Cost of Revenue of $74.70 thousand for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-11-14.
Discontinued › Expense Statement
us-gaap:CostOfRevenue · last filed 2023-11-14
- bioAffinity Technologies, Inc. cost of revenue for the quarter ending 2023-09-30 was $74.70K, a 51067.12% increase year-over-year.
- bioAffinity Technologies, Inc. cost of revenue for the quarter ending 2023-06-30 was $1.23K, a 745.21% increase year-over-year.
- bioAffinity Technologies, Inc. cost of revenue for the quarter ending 2023-03-31 was $87.00.
- bioAffinity Technologies, Inc. cost of revenue for the quarter ending 2022-12-31 was $175.00.
- bioAffinity Technologies, Inc. cost of revenue for fiscal 2022 was $467.00.
| Period end | Cost of Revenue 3 month | Cost of Revenue 6 month | Cost of Revenue 9 month | Cost of Revenue 12 month |
|---|---|---|---|---|
| 2023-09-30 | $74.70K 10-Q · filed 2023-11-14 | $75.94K derived: sum of 2 quarters · filed 2023-11-14 | $76.03K 10-Q · filed 2023-11-14 | $76.20K derived: sum of 4 quarters · filed 2023-11-14 |
| 2023-06-30 | $1.23K 10-Q · filed 2023-08-14 | $1.32K 10-Q · filed 2023-08-14 | $1.50K derived: sum of 3 quarters · filed 2023-08-14 | $1.64K derived: sum of 4 quarters · filed 2023-11-14 |
| 2023-03-31 | $87.00 10-Q · filed 2023-05-15 | $262.00 derived: sum of 2 quarters · filed 2023-05-15 | $408.00 derived: sum of 3 quarters · filed 2023-11-14 | $554.00 derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-12-31 | $175.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $321.00 derived: sum of 2 quarters · filed 2023-11-14 | $467.00 derived: sum of 3 quarters · filed 2023-11-14 | $467.00 10-K · filed 2023-03-31 |
| 2022-09-30 | $146.00 10-Q · filed 2023-11-14 | $292.00 derived: sum of 2 quarters · filed 2023-11-14 | $292.00 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $146.00 10-Q · filed 2023-08-14 | $146.00 10-Q · filed 2023-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |